These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 15596736

  • 1. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.
    Vartanian TK, Zamvil SS, Fox E, Sorensen PS.
    Neurology; 2004 Dec 14; 63(11 Suppl 5):S42-9. PubMed ID: 15596736
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B, Jacobs LD.
    Drugs; 2000 Mar 14; 59(3):401-10. PubMed ID: 10776827
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T, Sölberg Sørensen P, Rice G.
    J Neurol; 2004 Jun 14; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [Abstract] [Full Text] [Related]

  • 12. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J, So TY.
    Drugs; 2012 Jun 18; 72(9):1195-211. PubMed ID: 22642799
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
    Prince HE, Lapé-Nixon M, Audette C, Van Horn K.
    J Neuroimmunol; 2007 Oct 18; 190(1-2):165-9. PubMed ID: 17889376
    [Abstract] [Full Text] [Related]

  • 15.
    Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A.
    ; 2010 08 18. PubMed ID: 21348046
    [Abstract] [Full Text] [Related]

  • 16. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 17. Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.
    Stuart WH, Cohan S, Richert JR, Achiron A.
    Neurology; 2004 Dec 14; 63(11 Suppl 5):S19-27. PubMed ID: 15596732
    [Abstract] [Full Text] [Related]

  • 18. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V.
    J Korean Med Sci; 2013 Dec 14; 28(12):1801-6. PubMed ID: 24339712
    [Abstract] [Full Text] [Related]

  • 19. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD, Quinless JR, Jotkowitz A, Beaton P, Neutralizing Antibody Study Group.
    Neurology; 2001 Sep 25; 57(6):1080-4. PubMed ID: 11571337
    [Abstract] [Full Text] [Related]

  • 20. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F, Schellekens H, Bertolotto A.
    J Neurol; 2004 Jun 25; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.